Objective: Permanent mild-to-severe brain injury with neurologic sequelae remains a significant source of postoperative morbidity in cardiovascular surgery. There is increasing evidence that erythropoietin confers neuroprotective effects in various conditions of neuronal damage, such as hypoxia and cerebral ischaemia. Using a surviving porcine model, this study evaluates whether systemic treatment with erythropoietin induces brain protection in deep hypothermic circulatory arrest (DHCA). Methods: Sixteen pigs (42 AE 3 kg) randomly assigned into two groups (n = 8) were subjected to 60 min of DHCA at an intracerebral temperature of 20 8C. The animals of the erythropietin group were treated perioperatively with 500 IU kg À1 of recombinant human erythropoietin on 3 consecutive days beginning the day before surgery. Intracerebral monitoring was performed by subcortical microdialysis, brain tissue oxygenation, measurement of brain temperature and intracranial pressure. Neurologic recovery was evaluated daily. Perioperative S100b protein serum level was determined. The brains were harvested on the postoperative day 6 after perfusion fixation. Multiple brain regions were investigated histologically for hypoxic-ischaemic damage. Results: The subcortical brain microdialysis detected significant increase of glycerol and lactate concentrations in both groups (P = 0.0001) with considerably higher concentrations in the brain of control animals (P = 0.011). There were no significant differences in neurological outcome (P = 0.15). Erythropoietin-treated animals tended to a more complete and rapid neurological recovery. By contrast, none of the animals in the control group achieved complete neurological recovery. S100b protein as a putative marker of cerebral injury tended to be higher in the control group. Brain infarction was detectable in all control animals but only in two erythropoietin-treated animals. Conclusion: These results suggest some beneficial neuroprotective effects of erythropoietin in this model of global brain ischaemia induced by 1 h of hypothermic circulatory arrest. #
Introduction
Erythropoietin (Epo), a haematopoietic factor regulating erythroid progenitor cells, is also produced in the central nervous system (CNS) of rodents, primates and humans [1, 2] . It has been demonstrated to have remarkable neuroprotective potential in cell culture and animal models of disease [3, 4] . Recent in vitro and in vivo studies suggest that Epo is an essential mediator of ischaemic and hypoxic preconditioning [5, 6] . It relies on a broad array of cellular signal transduction pathways to prevent neuronal injury by programmed cell death [7] [8] [9] . Furthermore, preconditioning with Epo has been shown to protect neurons in models of ischaemic and degenerative damage due to excitotoxins and consequent generation of free radicals, including nitric oxide (NO). These data strongly support the evaluation of Epo as a well-tolerated agent for neuroprotective treatment in cardiac surgery.
Despite dramatic reduction in mortality following surgery for complex congenital heart defects and aortic arch surgery in recent years, permanent mild-to-severe brain injury with neurologic and developmental sequelae remains a significant source of postoperative morbidity [10] . Global cerebral ischaemia related to cardiopulmonary bypass (CPB) and deep hypothermic circulatory arrest (DHCA), used in the repair of the cardiovascular defects, appears to play an important role in neurologic morbidity [11] . The cardiac surgeon is in the unique position of being able to perform elective preconditioning of the brain before prolonged cerebral ischaemia.
This study aimed to investigate whether pharmacologic preconditioning with Epo might be able to attenuate neurologic injury in DHCA.
Material and methods
The procedures and animal care conformed to the European Convention on Animal Care and German Law on the Protection of Animals. The study was approved by the institutional ethics committee. Sixteen German landrace pigs aged 16-17 weeks with an average body weight of 42 AE 3 kg were randomly assigned to two groups treated with Epo (n = 8) or placebo (n = 8). Randomisation was carried out before the start of the protocol by a member of the laboratory. All members of the study group were blinded to the treatment. In the Epo group, the animals were treated on three consecutive days: 24 h before and after DHCA with 500 IU kg À1 Epoetin b (NeoRecormon 50000 Multidose; Roche Co, Basel, Switzerland) subcutaneously and, on the operative day, 3 h before circulatory arrest by the same dose, intravenously. In the control group, the identical volume of 0.9% NaCl was administered at the same sites and time points.
Anaesthesia
The pigs were premedicated intramuscularly with ketamine hydrochloride (10 mg kg ) using infusion pumps.
Neuromonitoring
After induction of general anaesthesia, three burr holes were made in three quadrants of the fronto-parietal area of the skull, followed by insertion of three bolt systems. Microprobes were placed through the bolts subcortically at a depth of 10 mm below the level of the dura.
Microdialysis
A CMA70 bolt catheter (CMA/Microdialysis; Solna, Sweden) was inserted through an IM1 single-lumen bolt (Licox IMC Bolt Systems; Integra NeuroSciences, Plainsboro, NJ, USA) in the left-upper quadrant. The catheters were perfused with isotonic sodium chloride and a constant flow was maintained (0.3 ml min À1 ) using a microdialysis pump (CMA 106 MD pump). The dialysates were collected every 30 min beginning 2 h before CPB until extubation. Dialysates were stored at À20 8C until further analysis. The concentrations of cerebral tissue glucose, lactate, pyruvate, glutamate and glycerol were measured with a microdialysis analyser (CMA 600, CMA/ Microdialysis).
Brain tissue oxygenation and temperature
Through an IM3 triple-lumen bolt in the left lower quadrant, an Oxygen Catheter microprobe and a temperature microprobe were inserted into the brain tissue (IM3.ST Complete Licox IMC probe kit; Integra NeuroSciences, Plainsboro, NJ, USA) and connected to the Licox CMP monitor.
Intracranial pressure
Through a Kamino bolt system in the right-upper quadrant, intracerebral pressure was measured (MPM-1; Kamino, Integra NeuroSciences, Plainsboro, NJ, USA).
Surgical procedure
The left femoral artery and vein were cannulated with an indwelling catheter for continuous arterial blood and central venous pressure monitoring. Urine output was monitored using a suprapubic catheter. The heart was then exposed through a right antero-lateral thoracotomy at 4th intercostal space and the 4th rib was partly resected. After systemic anticoagulation with heparin (400 IU kg À1 ), an 18F arterial cannula (Jostra AG, Hirrlingen, Germany) was inserted into ascending aorta, followed by cannulation of the right atrial appendage with a 34/39F two-stage cannula. CPB was initiated and all animals were cooled to an intracerebral temperature of 20 8C over 60 min, followed by 60 min of DHCA (Fig. 1) . Cardiac arrest was induced by adding potassium chloride (1 mEq kg À1 ) to the perfusate, and topical cardiac cooling was applied. Rectal and cerebral temperatures were maintained using ice packs. During the cooling phase, the left ventricle was vented using a 14F vent catheter inserted through the right upper pulmonary vein. After 60 min reperfusion, the animals were weaned off CPB at 36 8C. Intravenous protamine (5 mg kg À1 ) was given to reverse the heparin effect and the thorax closed.
Cardiopulmonary bypass (CPB)
The CPB circuit consisted of a roller pump (Stöckert Instumente; Munich, Germany), sterile tubing and a membrane oxygenator (Quadrox, Jostra AG, Hirrlingen, Germany). The pump circuit was primed with 1000 ml of 0.9% NaCl, methylprednisolon (20 mg kg ). The perfusate temperature was controlled by the membrane oxygenator (Quadrox) with integrated heat exchanger. CPB flow was set at 100 ml kg À1 min À1 using pH-stat strategy. After cooling, perfusion was stopped for 1 h. Reperfusion was begun at 25 ml kg À1 min À1 for 10 min followed by 100 ml kg À1 min
À1
. The heart was defibrillated as necessary at 25 8C. The animals were re-warmed to a rectal temperature of 36 8C over 60 min of reperfusion. Ventilation was started 10 min before weaning off CPB.
Postoperative management
Postoperatively, the animals were sedated with 1-2% isoflurane and mechanically ventilated. Analgesia was achieved by Buprenorphine. Intravenous cephazoline was administered every 8 h for perioperative antibiotic prophylaxis. The animals were extubated at 8-10 h after the arrest. They were offered water and food ad libitum. On postoperative day 1, the last dose of erythropoietin was administered subcutaneously. From postoperative day 1 onwards, analgesia was achieved by subcutaneous carprofen and antibiotic prophylaxis was performed by intramuscular application of benzathin-penicillin and streptomycin (Veracin-comp.).
Blood gas analyses
Arterial blood gas values, including electrolytes, glucose, base excess, bicarbonate, pH, haemoglobin, haematocrit and lactate concentrations, were measured at baseline, every 10 min on CPB and hourly until extubation.
Biochemical analyses
Blood samples were drawn before application of the second dose of rhEpo, at the end of the operation and on postoperative day 1 and postoperative day 6 to measure S100b protein, erythropoietin, troponin I, creatine kinase, lactate dehydrogenase, alkaline phosphatase, aspartate transaminase, alanin transaminase, blood urea nitrogen and creatinine concentrations. S100b protein (Sangtec 100; DiaSorin SpA, Saluggia, Italy) and erythropoietin (Nichols Institute Diagnostics, San Clemente, CA, USA) concentrations were determined using twosite chemiluminescence immunoassay.
Neurological assessment
Neurological assessment was performed in all animals for a total of 6 days at 12-h intervals by one veterinarian blinded to the study. Neurologic scoring was performed according to a 9-point behavioural scale to assess deficits in level of consciousness, appetite and movement and a score of 3 was assigned to each category. The scores from each category were summed. A minimum score of zero indicates brain death, whereas a total score of 9 represents no deficits. All animals were kept under close observation for clinical evidence of seizure activity.
Brain perfusion-fixation
On postoperative day 6, all animals were anaesthesised with intramuscular ketamine hydrochloride (50 mg kg À1 ). After endotracheal intubation, the animals were placed on a mechanical ventilator. The thorax was reopened at the operative site. The brachiocephalic artery was dissected free and cannulated with a 14F vent catheter. The right atrium was cannulated with a single venous catheter, which was forwarded into the innominate vein to vent the cerebral effluent. Heparin 100 IU kg À1 was given intravenously and the animal was euthanised with intravenous KCL. The brain was perfused with 5 l NaCl followed by 4 l of 4% buffered paraformaldehyde (pH 7.4) to fix the brain in situ. The brain was then removed in toto, weighed and stored submerged in 4% paraformaldehyde.
Histologic assessment
After formalin fixation, the brains were cut into 3-mmthick sections. Thereby, the cerebrum was cut in coronal sections, while the brainstem was cut in transverse sections. Tissue samples for embedding in paraffin were selected from both hemispheres from the following regions: frontal lobe, hippocampus CA1, hippocampus CA2-4, insular lobe, striatum (putamen and globus pallidus), caudate nucleus and thalamus. Furthermore, samples from the pons, medulla oblongata, vermis cerebelli and dentate nucleus were selected for histologic examination. Thus, at least 18 brain regions were examined in all animals. Macroscopically conspicuous areas not captured with the above-mentioned samples (e.g., border zone infarctions) were additionally collected for histological examination. All samples were routinely stained with haematoxylin and eosin to determine cell morphology. Sections containing putamen, globus pallidus and caudate nucleus were additionally stained with cresyl violet allowing better topographic demarcation of these brain regions due to myelin staining. All sections of each animal were screened by an experienced senior pathologist blinded to treatment of individual animals.
Brain regions were scanned microscopically for areas with most severe hypoxic cell damage (hot spots). Evidence of hypoxic-ischaemic injury was indicated by the presence of shrunken neurons with pyknotic nuclei and eosinophilic cytoplasm. In the hot spots, the numbers of neurons were counted in 10 high-power fields at 200-fold magnification (2.5 mm 2 ). In anatomically smaller brain regions (e.g. hippocampus and dentate nucleus), at least 100 neurons were evaluated. Neurons showing typical hypoxic cell damage and neurons with inconspicuous morphology were counted separately. In areas bearing brain infarction, the area of infarction was chosen as the hot spot. As in an infarction, complete neuronal cell damage is present when 100% of neurons per square millimetre were calculated to be damaged. For statistical evaluation, the absolute numbers of damaged neurons per square millimetre in an infarction was determined by counting neurons per square millimetre in the region immediately adjacent to the infarction.
Statistics
Continuous variables are expressed as mean AE SD or median (interquartile range). Statistical analysis was performed with JMP statistical software. For each perioperative time point, differences between the groups in the decadic logarithms of microdialysis data and arterial lactate concentrations were examined by repeated ANOVA measurements. Other continuous variables were compared in the same manner. The Wilcoxon rank-sum test was used to compare medians of neurobehavioral scores and decadic logarithms of percentages of hypoxic neuronal cells. Furthermore, using an ANCOVA with the nominal factor pig (modelled as random effect) and the continuous factor time, it was examined whether the decadic logarithms of microdialysis data significantly changed within the post-arrest interval. P values <0.05 were regarded as statistically significant.
Results

Mortality and morbidity
Both groups showed identical survival outcome. Two animals of control group and two EPO-treated animals died within 2 days after operation due to respiratory distress after extubation. They were replaced in a blinded fashion.
Haemodynamic and physiologic data
There were no significant differences between Epo and control group with respect to rectal and intracerebral temperature, haematocrit, blood gas measurements and haemodynamic parameters (Table 1 ).
Biochemical analyses
The serum Epo level was markedly increased in Epotreated animals after subcutaneous and intravenous injection ( Fig. 2A) . The S100b protein tended to be higher in the control group at the end of the operation (P = 0.08) and the day after (Fig. 2B) . Other biochemical parameters were comparable in both groups.
Microdialysis
There was a substantial increase of brain lactate and glycerol concentrations from baseline in both groups with a peak level at the end of re-warming (P = 0.0001) (Fig. 3A and B) . The concentrations of lactate and glycerol were higher in the control group, reaching essential difference between the groups 5 and 8 h after the arrest, respectively (P = 0.011). Brain glucose and pyruvate levels were markedly increased in both groups 2 h after the arrest (P = 0.0001) and tended to be higher in the control group (Fig. 3C ). Brain glutamate decreased in control and Epo animals considerably after the arrest or 1 h later (P = 0.012), respectively, and showed further decrease in subsequent periods of neuromonitoring below the baseline levels (Fig. 3D) . Lactate/glucose ratio showed similar pattern in both study groups throughout the experiment with a peak increase at the end of the arrest (Fig. 3E ). Data are mean AE SD. P values represent tests using repeated measures analysis of variance to compare rates of change between the groups at multiple time points. MAP indicates mean arterial pressure; CVP, central venous pressure; HCA, hypothermic circulatory arrest; CPB, cardiopulmonary bypass; T, temperature; ICP, intracranial pressure; minutes and hours indicate time interval after end of hypothermic circulatory arrest and start of re-warming.
Intracranial pressure and brain tissue oxygenation
Intracranial pressure was increased in both groups after the reperfusion period, with a higher tendency in the control group ( Table 1 ). The brain tissue oxygenation was significantly higher in the control group after CPB (P = 0.01).
Neurologic assessment results
Although not significant (P = 0.15), there was a better neurological recovery in the Epo group. The Epo-treated animals were characterised by a more rapid and complete recovery (Fig. 4) . By contrast, none of the animals in the control group had neurobehavioral scores of more than 8 until the end of the observation period.
Histopathologic results
Numbers and distribution of hypoxic neurons were similar in both groups (Table 2 ). There were no essential differences in the number of hypoxic neurons between control animals and those with Epo treatment. Histologic damage was found predominantly in the frontal cortex. Brain infarctions were detected in all surviving animals of the control group, but only in two of the Epo animals. All brain infarctions identified showed macrophage infiltration indicating the onset of brain injury at least 2-4 days before euthanasia.
Discussion
There is increasing evidence suggesting Epo as being an effective neuroprotective agent [12] . First identified as a haematopoietic cytokine, expression of Epo and Epo receptor could also be detected in the nervous system [13] . It acts in a coordinated fashion at multiple levels in the nervous system, including limiting the production of tissue-injuring molecules such as oxygen-derived free radicals and glutamate, attenuation of apoptosis, modulation of neurotransmission and stimulation of angiogenesis [6] [7] [8] 14] . Since hypothermic reduction of cellular metabolism is not absolute in DHCA, new strategies are needed to enhance the ischaemic tolerance of the brain. The rationale for our experiment was to improve cerebral tolerance to extended periods of circulatory arrest by perioperative Epo treatment. Our study tested the hypothesis of whether Epo could protect the brain during temporary global ischaemia induced by 60 min of DHCA.
Although statistical analysis did not indicate better neurological outcomes in the Epo-treated animals, they were characterised by a more rapid and complete recovery throughout the postoperative period as well as by reduced rate of brain infarction than controls. In accordance with previous reports, no significant differences in total histopathologic findings could be shown [15] .
Furthermore, we could show only a tendency for higher S100b protein serum levels in the control group after DHCA. S100b has been proposed as a biochemical marker for cerebral injury during cardiac operations [16] . It also has been shown to correlate with infarct size and functional outcome after acute ischaemic stroke [17, 18] . However, previous studies suggested that a major portion of circulating S100b protein after extracorporeal circulation may be of extracerebral origin, particularly due to the use of cardiotomy suction as performed in the present study [19, 20] .
Reduction of ischaemic neuronal damage and neurological dysfunction by Epo has been reported in other animal models of cerebral ischaemia [21] . Encouraged by multiple preclinical investigations demonstrating beneficial effects of Epo on neuronal survival and functional recovery as well as the long-term experience with rhEpo as an excellent, safe compound, clinical trials evaluating its neuroprotective potential in cerebral ischaemia are already ongoing. A recent, double-blind randomised proof-of-concept clinical trial has demonstrated significant improvement in outcome of stroke patients who were administered rhEpo intravenously within 8 h of the onset of symptoms [22] .
However, the main significant finding of our present study was evidence of beneficial biochemical effects of Epo in the brain during DHCA. Performing subcortical microdialysis of the brain, a reliable method for biochemical neuromonitoring [23] , we could show a substantial reduction of intraparenchymal glycerol and lactate levels in Epo-treated animals reaching significance 5 and 8 h after arrest, respectively. Elevated brain tissue glycerol concentrations have been associated with brain tissue damage, chiefly during or after cerebral ischaemia and are proposed as a stable post-ischaemic indicator of ischaemia-induced lipolysis of cell membrane [24] . Furthermore, higher lactate and glycerol concentrations in the brain have been correlated with worse postoperative outcome after experimental DHCA [23] .
The dose of Epo and the dosing schedule might account for differences that we report compared with other studies [15, 25] . For achieving sufficient Epo concentrations in the cerebrospinal fluid, a daily administration of high-dose Epo is required to cross the blood-brain barrier [26] . Since exacerbation of CNS injury may occur secondary to postoperative hypoxia or low cardiac output, Epo treatment should be continued after surgical intervention. However, the pharmacokinetics of systematically administered Epo under conditions of global brain ischaemia and changes of the blood-brain barrier remain sources of controversy and subjects of further clinical and laboratory investigations [27] . Due to potentially undesirable side effects, new derivatives of Epo have recently been developed with potent cytoprotective effects without haematopoietic activity [28] .
In conclusion, this study shows the occurrence of cellular injury in the brain at biochemical and clinical level after DHCA and demonstrates that this could be attenuated by perioperative administration of recombinant human erythropoietin.
Our data suggest that perioperative treatment with Epo beginning 24 h before induction of global brain ischaemia during HCA and continuation of the treatment after surgery ameliorates significantly cerebral metabolic recovery although significant differences in neurologic outcome could not be induced. The potential neuroprotection conferred by Epo during DHCA could be achieved by a combination of the known beneficial effects of Epo within CNS. However, both the timing and the dose of Epo used for neuroprotection seem to play a critical role for achieving sufficient cerebrospinal fluid levels at the time of surgery. Future studies will be needed to more precisely define the mechanism of Epo action in limiting neurologic damage in DHCA.
